Photodynamic Therapy Is Effective Against Candida auris Biofilms
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Fungal infections are increasing in prevalence worldwide. The paucity of available antifungal drug classes, combined with the increased occurrence of multidrug resistance in fungi, has led to new clinical challenges in the treatment of fungal infections. Candida auris is a recently emerged multidrug resistant human fungal pathogen that has become a worldwide public health threat. C. auris clinical isolates are often resistant to one or more antifungal drug classes, and thus, there is a high unmet medical need for the development of new therapeutic strategies effective against C. auris. Additionally, C. auris possesses several virulence traits, including the ability to form biofilms, further contributing to its drug resistance, and complicating the treatment of C. auris infections. Here we assessed red, green, and blue visible lights alone and in combination with photosensitizing compounds for their efficacies against C. auris biofilms. We found that (1) blue light inhibited and disrupted C. auris biofilms on its own and that the addition of photosensitizing compounds improved its antibiofilm potential; (2) red light inhibited and disrupted C. auris biofilms, but only in combination with photosensitizing compounds; and (3) green light inhibited C. auris biofilms in combination with photosensitizing compounds, but had no effects on disrupting C. auris biofilms. Taken together, our findings suggest that photodynamic therapy could be an effective non-drug therapeutic strategy against multidrug resistant C. auris biofilm infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 7×
“auris clinical isolates have been reported to be resistant to one or more of the three major classes of antifungal drugs used to treat invasive fungal infections, with 90% resistant to at least one antifungal drug class, 30% resistant to at least two antifungal drug classes, and a handful displaying pan-resistance to…”
BackgroundMethodInfluentialSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202 · cited 2×
“The azoles and polyenes target the fungal cell membrane, while echinocandins target the fungal cell wall; thus, there is a need for new antifungal strategies with distinct mechanisms of action (Odds et al., 2003; Prasad et al., 2016).”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057 · cited 2×
“auris biofilms, and are composed of yeast-form cells, pseudohyphal cells, and hyphal cells, encased in an extracellular matrix composed of proteins, lipids, carbohydrates, and nucleic acids (Zarnowski et al., 2014; Mukherjee and Chandra, 2015; Nobile and Johnson, 2015; Gulati and Nobile, 2016).”
BackgroundSelf-citationAntimicrobial photodynamic therapy – what we know and what we don’t
Cieplik, F., Deng, D., Crielaard, W., Buchalla, W., Hellwig, E., Al-Ahmad, A., & Maisch, T. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1467876 · Cited by 902
Candida albicans biofilms: development, regulation, and molecular mechanisms
Gulati, M., & Nobile, C. J. (2016) · Microbes and Infection · doi:10.1016/j.micinf.2016.01.002 · Cited by 738
Self-citationAntifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593 · cited 1×
“Second, antifungal drugs, like the polyenes, are known to cause substantial toxicities in humans and are usually administered systemwide (Roemer and Krysan, 2014).”
BackgroundA Candida auris Outbreak and Its Control in an Intensive Care Setting
Eyre, D. W., Sheppard, A. E., Madder, H., Moir, I., Moroney, R., Quan, T. P., Griffiths, D., George, S., Butcher, L., Morgan, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714373 · Cited by 517
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422 · cited 2×
“Additionally, persister cells, defined as metabolically dormant phenotypic cell variants, are markedly difficult to eradicate within mature biofi lms using tradit ional antimicrobial drugs (Stewart, 2002; Lewis, 2010; Taff et al., 2013; Fox et al., 2015).”
BackgroundCandida auris : The recent emergence of a multidrug-resistant fungal pathogen
Forsberg, K., Woodworth, K., Walters, M., Berkow, E. L., Jackson, B., Chiller, T., & Vallabhaneni, S. (2019) · Medical Mycology · doi:10.1093/mmy/myy054 · Cited by 421 · cited 3×
“…in the context of C. auris infections, and in fact, the majority of Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 C. auris clinical isolates are resistant to at least one antifungal drug class (Lockhart et al., 2017; Cortegiani et al., 2018; Forsberg et al., 2019).”
BackgroundBiofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Sherry, L., Ramage, G., Kean, R., Borman, A., Johnson, E. M., Richardson, M. D., & Rautemaa-Richardson, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161320 · Cited by 420
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Borman, A. M., Szekely, A., & Johnson, E. M. (2016) · mSphere · doi:10.1128/msphere.00189-16 · Cited by 333
Novel Entries in a Fungal Biofilm Matrix Encyclopedia
Zarnowski, R., Westler, W. M., Lacmbouh, G. A., Marita, J. M., Bothe, J. R., Bernhardt, J., Lounes-Hadj Sahraoui, A., Fontaine, J., Sanchez, H., Hatfield, R. D., et al. (2014) · mBio · doi:10.1128/mbio.01333-14 · Cited by 315
Candida auris in Healthcare Facilities, New York, USA, 2013–2017
Adams, E., Quinn, M., Tsay, S., Poirot, E., Chaturvedi, S., Southwick, K., Greenko, J., Fernandez, R., Kallen, A., Vallabhaneni, S., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2410.180649 · Cited by 284
Candida auris Outbreak in a COVID-19 Specialty Care Unit — Florida, July–August 2020
Prestel, C., Anderson, E., Forsberg, K., Lyman, M., de Perio, M. A., Kuhar, D., Edwards, K., Rivera, M., Shugart, A., Walters, M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e3 · Cited by 237 · cited 2×
“…have also been reported for C. auris-SARS-CoV-2 coinfections in patients with underlying chronic conditions, such as diabetes mellitus and kidney disease (Chowdhary et al., 2020; Rodriguez et al., 2020; Allaw et al., 2021; De Almeida et al., 2021; Magnasco et al., 2021; Prestel et al., 2021).”
BackgroundReview on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
Kean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
Topical PDT in the Treatment of Benign Skin Diseases: Principles and New Applications
Kim, M., Jung, H., & Park, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161023259 · Cited by 133 · cited 1×
“Photodynamic therapy has been used for the past 40 years to treat oncologic skin conditions, and more recently to treat benign inflammatory skin conditions, such as acne vulgaris and viral warts (Agostinis et al., 2011; Kim et al., 2015; Cohen et al., 2016).”
BackgroundConserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance
Dominguez, E. G., Zarnowski, R., Choy, H. L., Zhao, M., Sanchez, H., Nett, J. E., & Andes, D. R. (2019) · mSphere · doi:10.1128/mspheredirect.00680-18 · Cited by 132 · cited 4×
“C. auris biofilm formation is thought to occur in four stages: adherence, initiation, maturation, and dispersal (Kean et al., 2018; Dominguez et al., 2019) (Figure 1A).”
BackgroundInfluentialCandida auris Infection and Biofilm Formation: Going Beyond the Surface
Horton, M. V., & Nett, J. E. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00143-7 · Cited by 132 · cited 3×
“…patients, C. auris is typically isolated from the skin, nares, wounds, axilla, and urinary tracts, as well as the bloodstream, bones, and cerebrospinal fluids of patients with severe invasive infections (Borman et al., 2016; Calvo et al., 2016; Morales-López et al., 2017; Horton and Nett, 2020).”
BackgroundPhotodynamic Therapy for Non-Melanoma Skin Cancers
Cohen, D., & Lee, P. (2016) · Cancers · doi:10.3390/cancers8100090 · Cited by 128
Shastri, P. S., Shankarnarayan, S. A., Oberoi, J., Rudramurthy, S. M., Wattal, C., & Chakrabarti, A. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.01.004 · Cited by 103
Candida auris : multi-omics signature of an emerging and multidrug-resistant pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S., Clair, G., Bredeweg, E., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · doi:10.1101/528232 · Cited by 99
Multi-omics Signature of Candida auris , an Emerging and Multidrug-Resistant Pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S. P., Clair, G. C., Bredeweg, E. L., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · mSystems · doi:10.1128/msystems.00257-19 · Cited by 99
Unique Cell Surface Mannan of Yeast Pathogen Candida auris with Selective Binding to IgG
Yan, L., Xia, K., Yu, Y., Miliakos, A., Chaturvedi, S., Zhang, F., Chen, S., Chaturvedi, V., & Linhardt, R. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00450 · Cited by 47 · cited 1×
“The C. auris cell wall, for example, contains distinct cell surface mannans that are absent from the C. albicans cell wall as well as elevated chitin levels relative to the C. albicans cell wall (Navarroarias et al., 2019; Zamith-Miranda et al., 2019; Yan et al., 2020).”
Background
Cited by
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Watkins, R. R., Gowen, R., Lionakis, M., & Ghannoum, M. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.535 · Cited by 68
“The ability of light to target multiple cellular components also decreases the chance of developing resistance mechanisms [57].”
BackgroundPsychogenetic, genetic and epigenetic mechanisms in Candida auris: Role in drug resistance
Rabaan, A. A., Eljaaly, K., Alfouzan, W. A., Mutair, A. A., Alhumaid, S., Alfaraj, A. H., Aldawood, Y., Alsaleh, A. A., Albayat, H., Azmi, R. A., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.012 · Cited by 14
Metadata
- Authors
- Bapat, P. S., & Nobile, C. J.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2021-09-03
- Volume
- 11
- Pages
- 713092-713092
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W3196404233
- Cited by
- 35
- References
- 27
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.